Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas

American Journal of Obstetrics and Gynecology

Volumn 212, Issue 2, 2015, Pages 188.e1-188.e6

  Usach, Irina ^a   Blansit, Kevin ^a,b   Chen, Lee May ^a   Ueda, Stefanie ^a   Brooks, Rebecca ^a   Kapp, Daniel S ^c   Chan, John K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PALO ALTO MEDICAL FOUNDATION   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

cancer origin; endometrial cancer; ovarian cancer; serous cancer; survival analysis

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CAUCASIAN; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; OVARY CARCINOMA; PERITONEUM CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; RACE DIFFERENCE; SURVIVAL RATE; UTERINE TUBE CARCINOMA; UTERUS CARCINOMA; YOUNG ADULT; CANCER GRADING; CARCINOMA; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; UTERINE TUBE TUMOR; UTERUS CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84921652072     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2014.08.016     Document Type: Article

References (31)

1. M.T. Goodman, and Y.B. Shvetsov Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004 Cancer Epidemiol Biomarkers Prev 18 2009 132 139
2. C.A. Hamilton, M.K. Cheung, and K. Osann Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
3. C.P. Crum, R. Drapkin, and A. Miron The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 2007 3 9
4. C.G. Przybycin, R.J. Kurman, B.M. Ronnett, Shih Ie M, and R. Vang Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34 2010 1407 1416
5. K.K. Zorn, T. Bonome, and L. Gangi Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer Clin Cancer Res 11 2005 6422 6430
6. K. Hemminki, M. Bevier, A. Hemminki, and J. Sundquist Survival in cancer of unknown primary site: population-based analysis by site and histology Ann Oncol 23 2012 1854 1863
7. D.M. Bello, E. Smyth, and D. Perez Anal versus rectal melanoma: does site of origin predict outcome? Dis Colon Rectum 56 2013 150 157
8. B.K. Erickson, M.G. Conner, and C.N. Landen Jr. The role of the fallopian tube in the origin of ovarian cancer Am J Obstet Gynecol 209 2013 409 414
9. K.N. Moore, K.M. Moxley, and A.N. Fader Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary Gynecol Oncol 107 2007 398 403
10. National Institutes of Health. Sunitinib malate in treating patients with persistent or recurrent clear cell ovarian cancer. 2013. Available at: ClinicalTrials.gov. Accessed July 5, 2013.
11. C. Tian, M. Markman, and R. Zaino CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study Cancer 115 2009 1395 1403
12. J. Brown, W.E. Brady, and J. Schink Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group Cancer 120 2014 344 351
13. J.J. Van Gompel, R.S. Sippel, T.F. Warner, and H. Chen Gastrointestinal carcinoid tumors: factors that predict outcome World J Surg 28 2004 387 392
14. R.C. Bast Jr. Molecular approaches to personalizing management of ovarian cancer Ann Oncol 22 Suppl 8 2011 viii5 viii15
15. T.K. Owonikoko, and F.R. Khuri Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation Am Soc Clin Oncol Educ Book 2013 [Epub ahead of print] doi:10.1200/EdBook-AM.2013.33.e395
16. C.D. Britten PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types Cancer Chemother Pharmacol 71 2013 1395 1409
17. E.L. Schubert, M.K. Lee, and H.C. Mefford BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2 Am J Hum Genet 60 1997 1031 1040
18. R.P. Zweemer, P.J. van Diest, and R.H. Verheijen Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations Gynecol Oncol 76 2000 45 50
19. G. Chene, A. Tchirkov, and E. Pierre-Eymard Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions Clin Cancer Res 19 2013 2873 2882
20. L.C. Horn, S. Kafkova, K. Leonhardt, C. Kellner, and J. Einenkel Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas Int J Gynecol Pathol 32 2013 339 344
21. F.F. Gao, R. Bhargava, H. Yang, Z. Li, and C. Zhao Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin? Hum Pathol 44 2013 1534 1543
22. R.J. Kurman, and Shih Ie M Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2008 151 160
23. R. Vang, Shih Ie M, and R.J. Kurman Fallopian tube precursors of ovarian low- and high-grade serous neoplasms Histopathology 62 2013 44 58
24. Cancer Genome Atlas Research Network C. Kandoth, and N. Schultz Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
25. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
26. A. Bashashati, G. Ha, and A. Tone Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling J Pathol 231 2013 21 34
27. I.G. Schauer, J. Zhang, and Z. Xing Interleukin-1beta promotes ovarian tumorigenesis through a p53/NF-kappaB-mediated inflammatory response in stromal fibroblasts Neoplasia 15 2013 409 420
28. M.S. Piver, Y. Tsukada, B.A. Werness, R.A. DiCioccio, A.S. Whittemore, and B.A. Ponder Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: a study by the Gilda Radner Familial Ovarian Cancer Registry Gynecol Oncol 78 2000 166 170
29. C.W. Tyler Jr., N.C. Lee, and S.J. Robboy The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol 164 1991 65 70
30. The North American Association of Central Cancer Registries. Springfield, IL: Registries of The North American Association of Central Cancer; 2014.
31. B.A. Virnig, J.L. Warren, G.S. Cooper, C.N. Klabunde, N. Schussler, and J. Freeman Studying radiation therapy using SEER-Medicare-linked data Med Care 40 2002 IV-49-54